Literature DB >> 3516063

A new syndrome of anosmia, ichthyosis, hypogonadism, and various neurological manifestations with deficiency of steroid sulfatase and arylsulfatase C.

N Sunohara, N Sakuragawa, E Satoyoshi, A Tanae, L J Shapiro.   

Abstract

We describe a family consisting of 3 affected men with congenital ichthyosis, anosmia, hypogonadism, nystagmus with decreased visual acuity, strabismus, hypopigmentation of the iris, and mirror movements of the hands and feet. Two of them had limitation of ocular movement and unilateral renal agenesis or hypoplasia. The condition appears to be inherited as an X-linked recessive trait. Clinical, pathological, and biochemical evaluations were compatible with a diagnosis of X-linked ichthyosis. Steroid sulfatase and arylsulfatase C activities in leukocytes and fibroblasts were markedly diminished in the affected patients. Their hypogonadism was due to decreased luteinizing hormone-releasing hormone secretion (hypogonadotropic). Hyposecretion of antidiuretic hormone was also recognized. Chromosome analysis of leukocytes and skin fibroblasts revealed a normal 46,XY male karyotype in all of the patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516063     DOI: 10.1002/ana.410190211

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

1.  Molecular studies of deletions at the human steroid sulfatase locus.

Authors:  L J Shapiro; P Yen; D Pomerantz; E Martin; L Rolewic; T Mohandas
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 2.  Albinism: modern molecular diagnosis.

Authors:  S M Carden; R E Boissy; P J Schoettker; W V Good
Journal:  Br J Ophthalmol       Date:  1998-02       Impact factor: 4.638

3.  An Xp22 microdeletion associated with ocular albinism and ichthyosis: approximation of breakpoints and estimation of deletion size by using cloned DNA probes and flow cytometry.

Authors:  R E Schnur; B J Trask; G van den Engh; H H Punnett; M Kistenmacher; M A Tomeo; R E Naids; R L Nussbaum
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

4.  Studies on cross-reacting material to steroid sulphatase in fibroblasts from patients affected by different types of steroid sulphatase deficiency.

Authors:  G Parenti; A Ballabio; A T Hoogeveen; C M Van der Loos; A C Jobsis; G Andria
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

5.  Analysis of a terminal Xp22.3 deletion in a patient with six monogenic disorders: implications for the mapping of X linked ocular albinism.

Authors:  A Meindl; D Hosenfeld; W Brückl; S Schuffenhauer; J Jenderny; A Bacskulin; H C Oppermann; O Swensson; P Bouloux; T Meitinger
Journal:  J Med Genet       Date:  1993-10       Impact factor: 6.318

Review 6.  Malformation syndromes: a review of mouse/human homology.

Authors:  R M Winter
Journal:  J Med Genet       Date:  1988-07       Impact factor: 6.318

7.  Kallmann syndrome and paranoid schizophrenia: a rare combination.

Authors:  Willem M A Verhoeven; Jos I M Egger; Johannes E Hovens; Lies Hoefsloot
Journal:  BMJ Case Rep       Date:  2013-01-17

8.  Moebius syndrome in association with hypogonadotropic hypogonadism.

Authors:  L E Brackett; L M Demers; A C Mamourian; C Ellenberger; R J Santen
Journal:  J Endocrinol Invest       Date:  1991 Jul-Aug       Impact factor: 4.256

9.  Deletions of the steroid sulphatase gene in "classical" X-linked ichthyosis and in X-linked ichthyosis associated with Kallmann syndrome.

Authors:  A Ballabio; G Sebastio; R Carrozzo; G Parenti; A Piccirillo; M G Persico; G Andria
Journal:  Hum Genet       Date:  1987-12       Impact factor: 4.132

10.  Definitive localization of X-linked Kallman syndrome (hypogonadotropic hypogonadism and anosmia) to Xp22.3: close linkage to the hypervariable repeat sequence CRI-S232.

Authors:  T Meitinger; B Heye; C Petit; J Levilliers; A Golla; C Moraine; B Dalla Piccola; W G Sippell; J Murken; A Ballabio
Journal:  Am J Hum Genet       Date:  1990-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.